|

Anti-PD-1 antibody Clinical Trials

5 actively recruiting trials across 1 location

▼ -1 trial since May 2026

Also known as: PD-1 blocking antibody

Pipeline

Phase 1: 1Phase 2: 2Phase 1/2: 2

Top Sponsors

  • The Second Affiliated Hospital of Chongqing Medical University2
  • TiumBio Co., Ltd.1
  • Han weidong1
  • Chinese PLA General Hospital1

Indications

Other4 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Phase 2
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Phase 1/2
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1

San Antonio, Texas1 trial

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NEXT Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.